A STUDY OF TREATMENT DISCONTINUATION FOR CHRONIC HEPATITIS B PATIENTS
Grant number: 1066536 | Funding period: 2014 - 2018
Guidelines currently recommend lifelong treatment for patients with chronic hepatitis B, with associated cost and risks of drug resistance and side effects. It has recently been suggested that up to 50% of patients may safely and successfully stop drug after long-term treatment. Our project will identify which patients can safely stop treatment, by performing detailed studies of the human immune system and the hepatitis B virus. This will be an important advance for patient care.
Related publications (2)
Secreted and intracellular cytokines are complementary measures for human monocytes treated with Toll-like receptor agonists
Yang Song, Julie Nigro, Lijia Yu, Mario Congiu, Narelle Skinner, Alexander Thompson, Kumar Visvanathan
Cytokine production by human peripheral blood mononuclear cells including monocytes, is frequently assessed by measuring secreted ..
Discontinuation of nucleoside analogue therapy in e-antigen-negative chronic hepatitis B: A meta-analysis
G Burns, S Vogrin, A Sutherland, V Sundararajan, K Visvanathan, A Thompson
BACKGROUND AND AIMS: Sustained virological suppression and hepatitis B surface antigen (HBsAg) loss have been described after nucl..